Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline and Theravance have announced the MAA submission for Anoro in Europe for patients with chronic obstructive pulmonary disease (COPD).
Subscribe to our email newsletter
The COPD therapy, administered using the ELLIPTA inhaler, is a combination of GSK573719 or umeclidinium bromide (UMEC), a long-acting muscarinic antagonist (LAMA) and vilanterol (VI), a long-acting beta2 agonist (LABA).
The regulatory application was submitted to the European Union for the investigational once-daily UMEC/VI combination therapy of 55/22mcg and 113/22mcg doses as a maintenance bronchodilator treatment to relieve symptoms in COPD patients.
Companies previously submitted a regulatory application for UMEC/VI in the US for COPD patients.